Literature DB >> 33248724

Portopulmonary Hypertension: Prevalence, Clinical and Hemodynamic Features.

Dulce Iliana Navarro-Vergara, Ernesto Roldan-Valadez, Guillermo Cueto-Robledo, Merly Yamile Jurado-Hernandez.   

Abstract

Portopulmonary hypertension (PoPH) is a vascular complication of portal hypertension. This study aims to identify the prevalence and analyzing the clinical and hemodynamic features of patients with PoPH from a cohort of pulmonary arterial hypertension (PAH) patients. A retrospective transversal descriptive and analytical study. Patients with PoPH taken from a PAH cohort. We compare with those reported in the literature. We found prevalence of 6.1% of 244 consecutive patients with PAH, 11 females and 4 males. The mean age was 62 years and the main etiology of portal hypertension was primary biliary cirrhosis. Statistical differences were found in mean pulmonary arterial pressure, pulmonary vascular resistance, right atrial pressure; we found levels lower than reported. We found significant differences in clinical and hemodynamic characteristics such as older age and hemodynamic parameters of less severity in the group of patients analyzed compared with reported data.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2020        PMID: 33248724     DOI: 10.1016/j.cpcardiol.2020.100747

Source DB:  PubMed          Journal:  Curr Probl Cardiol        ISSN: 0146-2806            Impact factor:   5.200


  2 in total

1.  Prevalence and Clinical Features of Portopulmonary Hypertension in Patients With Hepatic Cirrhosis: An Echocardiographic Study.

Authors:  Anany Gupta; Akshyaya Pradhan; Sanjay Mehrotra; Ravi Misra; Kauser Usman; Ajay Kumar; Shivani Pandey
Journal:  Cureus       Date:  2022-05-13

2.  The Different Effects of Direct Bilirubin on Portopulmonary Hypertension and Idiopathic Pulmonary Arterial Hypertension.

Authors:  Yuan Li; Hongling Qiu; Qinhua Zhao; Jing He; Rong Jiang; Wenhui Wu; Cijun Luo; Huiting Li; Lan Wang; Jinming Liu; Sugang Gong
Journal:  Int J Clin Pract       Date:  2022-02-03       Impact factor: 3.149

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.